Belite Bio (BLTE) Projected to Post Quarterly Earnings on Monday

Belite Bio (NASDAQ:BLTE) is projected to announce its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect Belite Bio to post earnings of ($0.56) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 2, 2026 at 4:30 PM ET.

Belite Bio (NASDAQ:BLTE) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.18. On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Belite Bio Stock Down 3.2%

Shares of BLTE opened at $164.11 on Friday. The stock has a market capitalization of $6.46 billion, a P/E ratio of -71.35 and a beta of -1.46. Belite Bio has a twelve month low of $49.00 and a twelve month high of $200.00. The firm has a fifty day simple moving average of $171.21 and a two-hundred day simple moving average of $128.54.

Institutional Investors Weigh In On Belite Bio

A number of large investors have recently modified their holdings of the stock. Wellington Management Group LLP bought a new position in Belite Bio in the fourth quarter worth about $991,000. BNP Paribas Financial Markets lifted its holdings in Belite Bio by 250.9% in the third quarter. BNP Paribas Financial Markets now owns 11,549 shares of the company’s stock worth $855,000 after buying an additional 8,258 shares during the period. Barclays PLC bought a new stake in Belite Bio during the 4th quarter valued at approximately $668,000. Marshall Wace LLP bought a new stake in Belite Bio during the 2nd quarter valued at approximately $547,000. Finally, Polymer Capital Management HK LTD purchased a new position in shares of Belite Bio during the 3rd quarter worth approximately $538,000. Institutional investors own 0.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Bank of America started coverage on shares of Belite Bio in a research note on Monday, January 26th. They set a “buy” rating and a $195.00 price objective for the company. Benchmark reissued a “buy” rating on shares of Belite Bio in a research note on Tuesday, March 3rd. HC Wainwright boosted their price target on Belite Bio from $185.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Maxim Group set a $200.00 price target on Belite Bio in a research report on Tuesday, December 2nd. Finally, Cantor Fitzgerald increased their price objective on Belite Bio from $200.00 to $266.00 and gave the stock an “overweight” rating in a report on Tuesday, March 3rd. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $202.33.

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.